KR20180107261A - Myc 조정제로서의 MAX 결합제 및 그의 용도 - Google Patents

Myc 조정제로서의 MAX 결합제 및 그의 용도 Download PDF

Info

Publication number
KR20180107261A
KR20180107261A KR1020187026354A KR20187026354A KR20180107261A KR 20180107261 A KR20180107261 A KR 20180107261A KR 1020187026354 A KR1020187026354 A KR 1020187026354A KR 20187026354 A KR20187026354 A KR 20187026354A KR 20180107261 A KR20180107261 A KR 20180107261A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
certain embodiments
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187026354A
Other languages
English (en)
Korean (ko)
Inventor
안젤라 엔. 쾰러
에릭 스테판
프란치스코 카발레로
딜런 비지트 닐
헬렌 엘. 에반스
니콜라스 비. 스트런츠
앤드류 첸
Original Assignee
메사추세츠 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메사추세츠 인스티튜트 오브 테크놀로지 filed Critical 메사추세츠 인스티튜트 오브 테크놀로지
Publication of KR20180107261A publication Critical patent/KR20180107261A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020187026354A 2016-02-16 2017-02-16 Myc 조정제로서의 MAX 결합제 및 그의 용도 Withdrawn KR20180107261A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295996P 2016-02-16 2016-02-16
US62/295,996 2016-02-16
PCT/US2017/018162 WO2017143059A1 (en) 2016-02-16 2017-02-16 Max binders as myc modulators and uses thereof

Publications (1)

Publication Number Publication Date
KR20180107261A true KR20180107261A (ko) 2018-10-01

Family

ID=58191662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026354A Withdrawn KR20180107261A (ko) 2016-02-16 2017-02-16 Myc 조정제로서의 MAX 결합제 및 그의 용도

Country Status (11)

Country Link
US (2) US10106555B2 (enExample)
EP (1) EP3416950A1 (enExample)
JP (1) JP2019505548A (enExample)
KR (1) KR20180107261A (enExample)
CN (1) CN109071456A (enExample)
AU (1) AU2017221422A1 (enExample)
BR (1) BR112018016133A2 (enExample)
CA (1) CA3012846A1 (enExample)
MX (1) MX2018009913A (enExample)
RU (1) RU2018132559A (enExample)
WO (1) WO2017143059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018132559A (ru) 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
EP3820847B1 (en) * 2018-07-09 2022-12-14 The Scripps Research Institute Improved compounds for myc inhibition
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
CN111274691A (zh) * 2020-01-16 2020-06-12 西安交通大学 一种分析预测max相材料可形成能力的方法
WO2021195360A1 (en) 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
WO2000018746A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
ATE363278T1 (de) 2001-09-14 2007-06-15 Novo Nordisk As Neue liganden für die hisb10 zn2+ stellen des insulin-hexamers in der r-konformation
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
AU2003291613B2 (en) 2002-04-30 2007-09-27 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
WO2005026112A2 (en) 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
WO2006005683A1 (en) 2004-07-09 2006-01-19 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
PT1746097E (pt) 2005-07-20 2010-04-15 Aventis Pharma Sa Heterociclos fundidos de 1,4-di-hidropiridina, processo para a sua preparação, utilização e composições que os contêm
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EA201001205A1 (ru) 2008-01-24 2011-04-29 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
WO2009108905A2 (en) 2008-02-28 2009-09-03 Life Technologies Corporation Fluorescence polarization herg assay
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
US8865909B2 (en) 2008-11-20 2014-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-biofilm agents
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
WO2011063502A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
KR101889993B1 (ko) 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
KR20140093607A (ko) 2011-05-11 2014-07-28 이데미쓰 고산 가부시키가이샤 신규 화합물, 유기 전기발광 소자용 재료 및 유기 전기발광 소자
KR20140060484A (ko) 2011-09-13 2014-05-20 이데미쓰 고산 가부시키가이샤 축합 복소 방향족 유도체, 유기 전계 발광 소자용 재료 및 그것을 이용한 유기 전계 발광 소자
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法
LT3418281T (lt) * 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
US9573963B2 (en) 2013-02-28 2017-02-21 Sumitomo Chemical Company, Limited Fused heterocyclic compound and pest control applications thereof
US8901164B2 (en) * 2013-03-07 2014-12-02 University Of Maryland, Baltimore Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
US9242944B2 (en) 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
CA2942574A1 (en) 2013-12-11 2015-06-18 The Scripps Research Institute Small molecule c-myc inhibitors
CA2968884A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
RU2018132559A (ru) 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения

Also Published As

Publication number Publication date
MX2018009913A (es) 2018-11-29
US20170233405A1 (en) 2017-08-17
WO2017143059A1 (en) 2017-08-24
US20190144466A1 (en) 2019-05-16
US10865213B2 (en) 2020-12-15
US10106555B2 (en) 2018-10-23
EP3416950A1 (en) 2018-12-26
RU2018132559A (ru) 2020-03-17
JP2019505548A (ja) 2019-02-28
BR112018016133A2 (pt) 2019-01-02
AU2017221422A1 (en) 2018-08-16
CN109071456A (zh) 2018-12-21
CA3012846A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
JP6989505B2 (ja) Ｍａｌｔ１阻害剤およびその使用
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP2021514958A (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP2019514884A (ja) Ｅｚｈ２インヒビターおよびそれらの使用
US10865213B2 (en) Max binders as MYC modulators and uses thereof
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
JP2021528470A (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
KR20160034379A (ko) 전사 인자의 억제제 및 그의 용도
AU2011224457B2 (en) Cdc7 kinase inhibitors and uses thereof
CN111825611B (zh) 4(1h)-奎诺酮衍生物及其用途
JP2021510733A (ja) がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP7389749B2 (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP2021502986A (ja) 新規イミダゾピリミジン化合物およびそれらの使用
CN113710660B (zh) Dot1l降解剂及其用途
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180912

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid